Strong revenue momentum offset by near-term margin compression

₹158.3Cr vs ₹124.9Cr Q1FY26 = 26.8% growth; core drivers PFN 31%, specialty 19%

Delivered 34.7% OPM; however, 250-350 bps below prior 37-38% recovery target guidance

PFN 31% growth and management stating 2% room for additional capacity growth aligns with claim

Specialty overall 26% margin; NSS operating in difficult European market; core unaffected by LPG

Qualitative claim not quantified in delivered results; significant but unverifiable

31% Q1 vs prior >10% guidance. Demand exceeds capacity; provides FY27 upside if pricing holds.

19% vs historic high-growth. Supply-side LPG disruption only; demand healthy. Recovery expected Q2.

8 approvals vs 6 prior quarter. Two strategic MOUs signed (Korean cathode, cell manufacturers). Qualification funnel deepening (21 lab, 16 pilot, 7 pre-commercial).

FY27 guidance revised to flattish/single-digit growth. European energy crisis forced largest customer downsize in Ireland. Recovery story pushed to FY28.

~3% currency impact, majority volume-driven (phosphates). Pricing pass-through mainly Q2.

Behind schedule on US customers. Significant growth next 2-3 years, possibly top 2-3 PFN products.

NSS dragged blended margin; LPG shortage caused <50% Q1 utilization. Core specialty mid-30s, bounces Q2.

Current capacity maxed (~2% headroom). Greenfield needed for growth continuation. FY28 sustain expected once online.

Dairy/infant nutrition energy-intensive. Largest customer (infant formula) scaled Ireland ops due to energy crisis. FY27 flattish, diversifying to developed markets post-new sales head.

Too early for specific margins. Asset turns and ROCE similar to PFN. Won't be lower than current PFN.

Partner managed distribution. Long-term margin expansion view justifies sales team. No competitive overlap post-exit.

No China sourcing (FEOC compliance required). Sources India + 3 other countries. Supply visibility secured via binding off-takes.

PFN >10% prior guidance beat (31% actual); specialty expected to return to historical growth; greenfield adds incremental from Q3

Currently 34.7%. Recovery drivers: greenfield utilization ramp, NSS market diversification (FY28), specialty cost leverage

Currently dragging blended specialty to 26%. India supply chain integration + sales head diversification expected to close gap

FDA approval expected Q1 FY27; five customer pre-approvals ongoing

Long-lead equipment deliveries on track (October 2026); statutory approvals progressing. Phase 2-3 timing subject to customer off-takes

NSS largest customer (infant formula, Ireland) scaled operations due to European energy crisis, delaying orders. FY27 guidance downgraded to flattish vs prior high-growth. Concentrated customer base.

EBITDA margin at 34.7% vs 37-38% target requires simultaneous: greenfield ramp-up, NSS normalization, specialty cost structure improvement. Any single factor delay compounds recovery timeline.

SAM Phase 1 (April 2027, 25 KTPA) positioned as long-term growth driver (100-200 KTPA target by 2030-31). Success hinges on: (1) two binding off-takes closing 2026, (2) qualification pipeline converting, (3) manufacturing scale-up execution.

April-May LPG shortage reduced specialty utilization to 33% (April) and <50% (May), limiting Q1 growth to 19%. While resolved by Q2, energy supply risk remains. Secured alternative supplies at higher cost.